‘The HemOnc Pulse’ Live: Unanswered Questions in T-Cell Lymphoma
May 30, 2024
auto_awesome
Experts at 'The HemOnc Pulse' Live discuss uncertainties in T-cell lymphoma management including transplant timing, novel agents for relapsed/refractory cases, potential of JAK inhibitors, exploring different CAR T constructs, and benefits of sequencing for actionable mutations.
The debate on transplants in T-cell lymphoma includes considerations for upfront hydrotherapy and stem cell rescue vs. waiting for relapse confirmation.
Emerging CAR T cell therapies and JAK inhibitors present potential advancements in treating specific T-cell lymphoma subtypes, necessitating further research collaborations.
Deep dives
Unanswered Questions in T Cell Lymphomas and Transplant Considerations
Debates around the role of transplants in T cell lymphomas remain unresolved, focusing on whether to proceed with hydrotherapy and stem cell rescue upfront or wait for relapse confirmation for fitter patients. The ongoing discussions emphasize the need for randomized studies to determine the efficacy of transplants in different settings, such as frontline remission. The controversy centers on selecting potentially favorable outcomes based on patient fitness and chemo-sensitivity.
Effectiveness of Transplants in T Cell Lymphomas in Relapse Setting
In the relapse setting of T cell lymphomas, the efficacy of transplants, particularly allografts, is under scrutiny due to varied patient responses and limited long-term success rates. Challenges arise from different disease behaviors and patient suitability for transplant treatments. Data from various studies highlight the complexities and uncertainties surrounding transplant outcomes, especially in T cell lymphomas.
Exploring Novel Agents, CAR T Cell Therapies, and Sequencing Strategies in T Cell Lymphomas
Emerging therapeutic approaches like CAR T cell therapies showcase potential benefits in certain T cell lymphoma subtypes, with ongoing studies focusing on CD4 and CD5-directed CAR constructs. The discussion extends to the use of JAK inhibitors in T cell diseases, emphasizing the need for innovative treatment options beyond Ruxolitinib. Developing sequencing strategies and identifying actionable mutations in T cell lymphomas present challenges due to the disease's rarity and the necessity for collaborative research efforts.
At the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management. The panelists were Mehdi Hamadani, MD, a Professor of Internal Medicine at the Medical College of Wisconsin, Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services at Rutgers Cancer Center, and Barbara Pro, MD, a Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode